Daniel Mark
Research Subjects
Daniel Mark has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
E.E. Klein
Department of Radiation Medicine, Northwell Health, Lake Success, NY
2 shared publicationsM. Ghaly
Department of Radiation Medicine, Northwell Health, Lake Success, NY
2 shared publicationsR. Meshrekey
Department of Radiation Medicine, Hofstra Northwell School of Medicine, Lake Success, NY
2 shared publicationsT.J. Ow
Montefiore Medical Center-Albert Einstein College of Medicine, Bronx, NY
2 shared publicationsA. Bontempo
Montefiore Medical Center-Albert Einstein College of Medicine, Bronx, NY
1 shared publicationA. Goenka
Department of Radiation Medicine, Northwell Health, Lake Success, NY
1 shared publication
Latest Publications
- Open Access
- 1 September 2019
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 105 (1) , E646-E647
Targeting Tumor-Associated Macrophages to Radiosensitize Glioblastoma in a Mouse Model
- 1 September 2019
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 105 (1) , E646-E647
Open AccessTargeting Tumor-Associated Macrophages to Radiosensitize Glioblastoma in a Mouse Model
- Open Access
- 3 July 2019
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 9, 601
Local Radiation Therapy for Palliation in Patients With Multiple Myeloma of the Spine
Purpose: The objective of this study was to assess a contemporary cohort of patients with multiple myeloma referred for palliative radiation to the mobile spine for clinical and radiological responses. Materials/Methods: The records of patients treated between 2009 and 2016 with radiotherapy for multiple myeloma of the spine were retrospectively reviewed. Demographics, systemic therapy, radiation dose, number of fractions, radiographic response based upon adapted RECIST criteria, and symptomatic response were recorded. Results: Eighty eight patients and 98 treatment courses were analyzed. All courses were analyzed for symptomatic response and 61 of the treatment courses were available for radiologic follow-up. The median follow-up was 9.7 months with a median radiation dose of 25 Gy (12.5–50 Gy) delivered in a median of 10 fractions (5–25 fractions). Fifty-four percent of patients had a high-risk lesion. Symptomatic response as measured by a decrease of ≤5 points on the pain related scale was 83% and 34% of patients had a decrease of >5 points. Of 35% of patients that had neurologic impairments prior to treatment, improvement was identified 83% of the time. Radiographic response was noted as 13% complete response, 16% partial response, 57% stable disease, and 13% disease progression. Specifically, high-risk lesions treated with radiation alone demonstrated no regression with only 10% demonstrating partial response. Conclusion: This retrospective series of patients treated with palliative intent for multiple myeloma using various dose and fractionation schemes showed favorable symptomatic relief in most patients. Radiographic response did not correlate with clinical response with fewer patients having radiologic disease regression. Longer follow-up is necessary to determine if the lack of radiologic response is associated with clinically relevant recurrent pain.
- 3 July 2019
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 9, 601
Open AccessLocal Radiation Therapy for Palliation in Patients With Multiple Myeloma of the Spine
Purpose: The objective of this study was to assess a contemporary cohort of patients with multiple myeloma referred for palliative radiation to the mobile spine for clinical and radiological responses. Materials/Methods: The records of patients treated between 2009 and 2016 with radiotherapy for multiple myeloma of the spine were retrospectively reviewed. Demographics, systemic therapy, radiation dose, number of fractions, radiographic response based upon adapted RECIST criteria, and symptomatic response were recorded. Results: Eighty eight patients and 98 treatment courses were analyzed. All courses were analyzed for symptomatic response and 61 of the treatment courses were available for radiologic follow-up. The median follow-up was 9.7 months with a median radiation dose of 25 Gy (12.5–50 Gy) delivered in a median of 10 fractions (5–25 fractions). Fifty-four percent of patients had a high-risk lesion. Symptomatic response as measured by a decrease of ≤5 points on the pain related scale was 83% and 34% of patients had a decrease of >5 points. Of 35% of patients that had neurologic impairments prior to treatment, improvement was identified 83% of the time. Radiographic response was noted as 13% complete response, 16% partial response, 57% stable disease, and 13% disease progression. Specifically, high-risk lesions treated with radiation alone demonstrated no regression with only 10% demonstrating partial response. Conclusion: This retrospective series of patients treated with palliative intent for multiple myeloma using various dose and fractionation schemes showed favorable symptomatic relief in most patients. Radiographic response did not correlate with clinical response with fewer patients having radiologic disease regression. Longer follow-up is necessary to determine if the lack of radiologic response is associated with clinically relevant recurrent pain.
- 1 November 2018
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 102 (3) , S39
Integrating Radiation Oncology into Inpatient Interdisciplinary Rounds with Medical Oncology and Palliative Care
- 1 November 2018
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 102 (3) , S39
Integrating Radiation Oncology into Inpatient Interdisciplinary Rounds with Medical Oncology and Palliative Care
- 1 October 2017
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 99 (2) , E432
Local Radiation Therapy for Palliation in Patients With Multiple Myeloma of the Spine
- 1 October 2017
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 99 (2) , E432
Local Radiation Therapy for Palliation in Patients With Multiple Myeloma of the Spine
- 1 October 2017
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 99 (2) , E520
Kypho-IORT: A New Treatment Paradigm for Pathological Fractures
- 1 October 2017
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 99 (2) , E520
Kypho-IORT: A New Treatment Paradigm for Pathological Fractures
- 1 December 2015
- Published by Elsevier in International Journal of Pediatric Otorhinolaryngology
- Vol. 79 (12) , 1995-2002
Proton therapy for the treatment of pediatric head and neck cancers: A review
- 1 December 2015
- Published by Elsevier in International Journal of Pediatric Otorhinolaryngology
- Vol. 79 (12) , 1995-2002
Proton therapy for the treatment of pediatric head and neck cancers: A review
- 1 November 2015
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 93 (3) , E332-E333
The Impact of Dietary Regimen Compliance and Sarcopenia in Head and Neck Cancer Patients Treated With Definitive Radiation Therapy
- 1 November 2015
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 93 (3) , E332-E333
The Impact of Dietary Regimen Compliance and Sarcopenia in Head and Neck Cancer Patients Treated With Definitive Radiation Therapy
- Open Access
- 1 November 2015
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 93 (3) , S209-S210
Gene Expression Biomarkers for Radiation Toxicity With a Focus on Mucositis in Head and Neck Cancers
- 1 November 2015
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 93 (3) , S209-S210
Open AccessGene Expression Biomarkers for Radiation Toxicity With a Focus on Mucositis in Head and Neck Cancers